- Home
- ELVN vs HIMX Comparison
ELVN vs HIMX Comparison
Compare ELVN & HIMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- HIMX
- Stock Information
- Founded
- ELVN 2016
- HIMX 2001
- Country
- ELVN United States
- HIMX Taiwan
- Employees
- ELVN N/A
- HIMX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- HIMX Semiconductors
- Sector
- ELVN Health Care
- HIMX Technology
- Exchange
- ELVN Nasdaq
- HIMX Nasdaq
- Market Cap
- ELVN 1.0B
- HIMX N/A
- IPO Year
- ELVN 2020
- HIMX 2006
- Fundamental
- Price
- ELVN $21.60
- HIMX $10.24
- Analyst Decision
- ELVN Strong Buy
- HIMX Buy
- Analyst Count
- ELVN 5
- HIMX 1
- Target Price
- ELVN $37.80
- HIMX $15.00
- AVG Volume (30 Days)
- ELVN 269.1K
- HIMX 5.5M
- Earning Date
- ELVN 03-13-2025
- HIMX 02-13-2025
- Dividend Yield
- ELVN N/A
- HIMX 2.87%
- EPS Growth
- ELVN N/A
- HIMX 10.98
- EPS
- ELVN N/A
- HIMX 0.44
- Revenue
- ELVN N/A
- HIMX $897,257,000.00
- Revenue This Year
- ELVN N/A
- HIMX $12.75
- Revenue Next Year
- ELVN N/A
- HIMX N/A
- P/E Ratio
- ELVN N/A
- HIMX $21.15
- Revenue Growth
- ELVN N/A
- HIMX N/A
- 52 Week Low
- ELVN $10.90
- HIMX $4.80
- 52 Week High
- ELVN $30.03
- HIMX $13.91
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- HIMX 52.38
- Support Level
- ELVN $20.40
- HIMX $9.21
- Resistance Level
- ELVN $22.42
- HIMX $10.52
- Average True Range (ATR)
- ELVN 1.25
- HIMX 1.08
- MACD
- ELVN 0.06
- HIMX -0.06
- Stochastic Oscillator
- ELVN 59.59
- HIMX 32.55
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.